A cheaper treatment can still waste money
A cheaper treatment can waste money. An expensive one can create value. And an intervention can be cost-effective yet still be impossible to fund at scale. That is the part of healthcare economics most dashboards miss.
Want each method explained in detail? The companion tool covers all nine, with the formula, when to use it, where it breaks and how it gets misused. Open the Value Lens →Short forms used in this edition6 terms
Imagine two treatments for the same condition. Standard care costs ₹40,000 per patient. A new option costs ₹70,000. If the conversation ends there, the answer looks obvious: the new treatment is 75% more expensive. But healthcare does not buy treatments. It buys health outcomes.
Price answers none of these questions on its own. It tells us only what one unit costs. Value needs a comparator, an outcome and a time horizon. Affordability needs scale.
02 — Nine lenses
Healthcare has nine ways to ask “is this worth it?”
What does one more unit of health cost?
Compares cost with a natural health outcome: admissions avoided, life-years gained, cases detected, blood pressure controlled. Best when outcomes are clinically specific.
What does better quantity + quality of life cost?
Uses a common measure such as the quality-adjusted life year, or QALY, which combines how long someone lives with how well, allowing unlike interventions to be compared on one health-value scale.
Do monetary benefits exceed monetary costs?
Converts benefits into money where feasible. Useful for broad programmes, productivity or societal returns, but the monetisation assumptions matter.
What happens to the actual budget?
Asks what adoption costs over a defined period for the eligible population. A cost-effective intervention can still fail this test.
If outcomes are equivalent, which option costs less?
Valid only when there is credible evidence that outcomes are meaningfully equivalent.
What does the disease itself cost?
Maps medical spending, non-medical costs and sometimes productivity loss. It shows burden, not whether a specific intervention is good value.
03 — Worked example
The ₹30,000 price gap is not the decision
Use a deliberately simple illustration. Standard care costs ₹40,000 and delivers 0.70 QALY over the chosen time horizon. The new option costs ₹70,000 and delivers 0.85 QALY.
Now add a purely illustrative willingness-to-pay benchmark of ₹2.5 lakh per QALY. On that benchmark the new option passes the value test. But if 100,000 patients are eligible and 20% receive it, the extra annual spend is ₹60 crore.
That is the central distinction: “cost-effective” means the additional health may justify the additional cost relative to alternatives. It does not mean the health system automatically has the money to fund every eligible patient.
View the worked example as a table
| Measure | Treatment A | Treatment B | Difference |
|---|---|---|---|
| Price per course | Lower | Higher by about ₹30,000 | ₹30,000 |
| What price alone tells you | Only what one unit costs. Nothing about what it achieves | ||
| What is missing | A comparator, an outcome measure, and a time horizon | ||
| Affordability | Needs eligible population, expected uptake, total budget impact and system capacity | ||
Illustrative figures chosen to show how the arithmetic behaves. Not prices for any real product. Use the interactive model above to change the assumptions.
04 — Live model
Change the assumptions and watch the decision move
On the default assumptions the model returns the same verdict as the worked example: good value per patient, and a total bill the budget cannot absorb. Changing uptake or the threshold flips it. The model below is educational, not an HTA recommendation. It makes the logic visible: comparator, incremental effect, threshold, eligible population and uptake all matter.
Cost-effectiveness + budget-impact calculator
Costs are per patient. Effect is in QALYs. The threshold is user-selected and is not presented as an official Indian threshold.
Comparator · Standard care
New intervention
Important: real HTA models include uncertainty, discounting, downstream events, adverse effects, time horizons, perspective, equity and sensitivity analysis. This calculator is intentionally stripped down so the decision logic is visible.
05 — The decision plane
Four quadrants, four very different conversations
“More expensive” is only one coordinate.
The second coordinate is health. The best case is dominant: better outcomes at lower cost. The worst is dominated: worse outcomes at higher cost. Most real decisions live in the trade-off quadrants.
06 — Four traps
Four phrases people use interchangeably, and should not
Cost-effective ≠ affordable
Good value per patient can still produce a huge total bill when the eligible population is large.
Cost-saving ≠ best health investment
A programme can save money but create little health, while another may cost more and generate much larger outcomes.
ROI ≠ health value
ROI answers a financial-return question. Cost-effectiveness answers a health-opportunity-cost question. Both can matter, but they are not substitutes.
Average cost ≠ incremental cost
Decisions are made against the next-best alternative. What matters is the extra cost for the extra outcome, not the absolute price alone.
07 — India already has the machinery
India already has the machinery for this
India has an institutional health technology assessment system, HTA for short, under the Department of Health Research. HTAIn exists to bring clinical effectiveness, safety, health economics and resource allocation into healthcare decisions. Its remit spans medicines, devices, diagnostics, procedures, public-health programmes and digital technologies, including AI.
Government of India institutional arrangement for evidence-informed health-technology decisions.
Evaluation is not only “does it work?” but also whether it represents value for money.
HTA evidence can inform government, providers and insurance/reimbursement decisions.
HTAIn's own manual makes a useful point about thresholds: a cost-effectiveness threshold should reflect scarce resources and foregone health opportunities, and it should not be used alone as a funding or affordability decision. That is exactly why the budget-impact question has to sit beside ICER.
The strategic shift: instead of asking whether India can “afford innovation,” ask which innovation produces enough additional health to justify its opportunity cost — and then design adoption so the budget can absorb it.
Official references: HTAIn — About · HTAIn Manual · HTAIn FAQ.
08 — Where the lens changes the decision
The same logic runs well past pharmaceuticals
High-cost cancer therapy
Do survival and quality-of-life gains justify the incremental treatment and adverse-event cost? Then ask what national or insurer uptake does to the budget.
CUA + budget impactAI diagnostic or triage tool
Model avoided tests and delays, but also false positives, clinician review time, integration cost and what happens downstream after detection.
CEA / cost-consequenceVaccination or screening
The upfront programme cost can look large while the avoided infections, cancers, admissions or productivity loss arrive over years.
CEA + CBARemote monitoring
A device is not valuable because it collects data. Value comes if it prevents deterioration, ED visits or admissions enough to offset programme and workflow costs.
CEA + ROI + budget impactDigital health has the same economic burden of proof as a drug or device: show the comparator, show the outcome, show the incremental cost, then show what happens at scale.
09 — A seven-question test
Before anyone says “this will save healthcare money”
- Compared with what? “No intervention” is often the wrong comparator if standard care already exists.
- Whose cost? Patient, hospital, payer, government and society can see different economics.
- What outcome? A process metric such as clicks or tests is not automatically a health outcome.
- Over what time? Prevention often spends now and returns value years later.
- What happens downstream? Earlier diagnosis can reduce late complications but increase near-term treatment spending.
- What happens at scale? Multiply the incremental cost by eligible patients and realistic uptake.
- Who wins and who loses? An efficient average can still worsen access or equity for a subgroup.
10 — So what?
The next rupee is the real unit of strategy
A health system never has unlimited money, clinicians, beds or time. Every decision therefore has an opportunity cost: funding one thing means not funding something else.
The useful leadership question is not “Which option is cheapest?” It is:
That one sentence connects clinical evidence, health economics and operating reality. Price tells you what you pay. Cost-effectiveness tells you what the extra health costs. Budget impact tells you whether the system can actually do it.
11 — Sources and evidence status
What is official and what is illustrative
Scope note: This edition explains decision logic, not a full HTA. Real evaluations require disease-specific clinical evidence, resource use, utilities, time horizon, discounting, uncertainty and sensitivity analysis.
Before citing externally: the worked example and the interactive model use illustrative figures chosen to show how the arithmetic behaves, not real prices for any named product. Cost-effectiveness thresholds are contested and India has not adopted a single official one, so any threshold shown is a reference point rather than a rule. HTAIn processes and NICE methods are cited as published; their application to any specific decision is my own.